Selective low level of protein kinase C isozyme in a tumor promoter-dependent mouse leukemia cell line.

Abstract	It was found that the activity of protein kinase C in the tumor promoter-dependent cell line (A65T) was significantly lower than that in the independent cell line (A65IND) which was mutated from the dependent cell line. On the other hand, there was no significant difference between these cell lines with regard to cAMP-dependent protein kinase activity. It was found that the maximal binding capacity of [20-3H]phorbol-12,13-dibutyrate of the tumor promoter-dependent cells is lower than that of the independent cells with similar affinities of the two cell lines. Moreover, we found that the level of immunoreactive antigen with monoclonal antibody for type III of protein kinase C in A65T cells was significantly lower than that in the A65IND cells. Thus, this selective lower level of type III of protein kinase C in A65T cells, as compared with A65IND cells means that this difference may be linked to its tumor promoter-dependent cell proliferation.
Authors	T Tanaka, M Hagiwara, H Hidaka, K Nunoki, H Ohta, K Onoda, M Ito, S Ohkubo, H Hiai, Y Nishizuka
Journal	Biochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 164 Issue 3 Pg. 1397-401 (Nov 15 1989) ISSN: 0006-291X [Print] United States
PMID	2590208 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibodies, Monoclonal Caenorhabditis elegans Proteins Carrier Proteins Isoenzymes Receptors, Drug phorbol ester binding protein phorbol ester receptor Phorbol 12,13-Dibutyrate Protein Kinases Protein Kinase C Tetradecanoylphorbol Acetate
Topics	Animals Antibodies, Monoclonal Caenorhabditis elegans Proteins Carrier Proteins Isoenzymes (genetics, metabolism) Leukemia, Experimental (enzymology, genetics) Mice Mutation Phorbol 12,13-Dibutyrate (metabolism) Protein Kinase C (genetics, metabolism) Protein Kinases (metabolism) Receptors, Drug (metabolism) Tetradecanoylphorbol Acetate (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!